Aardvark Therapeutics, Inc. (AARD) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$5.45

From 52W high−69.10%

Volume124972.00

Market cap$117.74M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$5.45

From 52W high

−69.10%

Volume

124972.00

Market cap

$117.74M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.6x

P/E (TTM)

—

RSI (14)

44.3

MomentumView details →

1D Return

−2.71%

YTD Return

−59.67%

SummaryUpdated Jun 1, 2026

Aardvark Therapeutics, Inc. (NASDAQ:AARD) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in San Diego, California. The company specializes in developing innovative small-molecule therapeutics that target the body's natural homeostatic pathways to treat metabolic diseases. Since its incorporation, Aardvark has focused on addressing rare metabolic disorders through a novel approach of activating bitter taste receptors in the gastrointestinal tract, representing a unique therapeutic strategy in the biotechnology sector.

Ask drillr about Aardvark Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.6x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−93.44%

ROA (TTM)

−85.80%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−53.59%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

−82.92%

MomentumView details →

1D Return

−2.71%

YTD Return

−59.67%

1Y Return

−51.38%

RSI (14)

44.3

vs 50D SMA

−15.66%

vs 200D SMA

−31.82%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

12.63x

Quick Ratio

12.63x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.66

EPS Surprise

24.52%

Beats (12Q)

3/12

Next Q EPS Est

−$0.72

Avg Surprise (4Q)

5.34%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−69.89M

Op. CF (TTM)

−69.41M

Next earningsNov 12, 2026 →

Latest newsMore news →

Moore Law PLLC announced it is investigating potential claims against the officers and directors of Aardvark Therapeutics, Inc. on behalf of shareholders.10d ago

A lawsuit was filed against Aardvark Therapeutics, Inc. on behalf of certain investors who purchased shares between February 13, 2025 and May 14, 2026, with a deadline of October 31, 2026 for investors to act.31d ago

Similar companies

OnKure Therapeutics, Inc.OKUR Tiziana Life Sciences LtdTLSA Coya Therapeutics, Inc.COYA Genelux CorporationGNLX Cibus, Inc.CBUS Milestone Pharmaceuticals Inc.MIST Find similar companies →

Latest newsMore news →

Moore Law PLLC announced it is investigating potential claims against the officers and directors of Aardvark Therapeutics, Inc. on behalf of shareholders.10d ago A lawsuit was filed against Aardvark Therapeutics, Inc. on behalf of certain investors who purchased shares between February 13, 2025 and May 14, 2026, with a deadline of October 31, 2026 for investors to act.31d ago Hagens Berman Sobol Shapiro LLP notified investors of a pending securities class action lawsuit against Aardvark Therapeutics, Inc. related to its IPO and subsequent securities purchases.31d ago